Panacea Biotec Shares Soar 10% on Major Dengue Vaccine Trial Milestone
Business
M
Moneycontrol•08-01-2026, 12:10
Panacea Biotec Shares Soar 10% on Major Dengue Vaccine Trial Milestone
- •Panacea Biotec shares surged up to 10% on BSE, reaching Rs 422.30, with market cap nearing Rs 2500 crore.
- •The surge followed the completion of enrollment for Phase III clinical trials of its dengue vaccine candidate, 'Dengioall'.
- •10,335 participants enrolled in the late-stage trial will be monitored for two years to assess efficacy and immunogenicity.
- •'Dengioall' is a tetravalent, single-dose vaccine using attenuated strains, expected to be India's first indigenous dengue vaccine.
- •The vaccine, under development since 2008, could be launched by 2027; stock rose 117% in 2 years.
Why It Matters: Panacea Biotec stock jumped on positive Phase III trial news for its indigenous single-dose dengue vaccine.
✦
More like this
Loading more articles...
